An international, open-label trial demonstrated the overall survival benefits of administering tebentafusp to HLA-A*02:01-positive patients with metastatic uveal melanoma.
A recent phase 3 trial published in The New England Journal of Medicine reinforced the long-term survival benefits of tebentafusp in patients with metastatic uveal melanoma who are HLA-A*02:01 positive.
Tebentafusp is a T-cell receptor-bispecific molecule designed to specifically target cluster of differentiation 3 (CD3) and glycoprotein 100 (gp100). At present, this is the only approved treatment for patients with metastatic uveal melanoma and a HLA-02:01-positive status.
In around 50% of patients with uveal melanoma, a metastatic disease develops, leading to worsened prognosis and dire expected survival outcomes of approximately 1 year. The emergence of tebentafusp has shown lots of promise for patient survival outcomes in its previous trials.
This development has been important considering that immune-checkpoint inhibitors—which can drastically alter outcomes in cutaneous melanoma—are relatively ineffective in cases of metastatic uveal melanoma. In this report, researchers provided an updated analysis from the phase 3 IMCgp11-202 trial that showcased the safety and efficacy of tebentafusp in this patient population after a 3-year follow-up.
Between March 2017 and June 2020, 378 HLA-A*02:01-positive patients were randomly assigned to a group treated with tebentafusp (n = 252) and a control group (n = 126; patients treated with dacarbazine, ipilimumab, or pembrolizumab). With a follow-up of at least 3 years, the tebentafusp group exhibited a median survival of 21.6 months, whereas the control group exhibited a median survival rate of 16.9 months (HR, 0.68; 95% CI, 0.54-0.87). At 1, 2, and 3 years, the percentage of surviving patients who received tebentafusp was 72%, 45% and 27%, respectfully. The control group had a survival rate at these intervals of 60%, 30%, and 18%, respectfully. Additionally, the researchers noted that a higher proportion of patients treated with tebentafusp than those in the control group experienced any shrinkage of tumors (40% vs 24%).
Some adverse side effects were observed in the tebentafusp group. Among these effects, the most prevalent were hypotension (38%), pruritus (70%), pyrexia (76%), and rash (83%). Patients typically experienced these events early on in tebentafusp therapy; no new events arose with long-term use and no treatment-related deaths took place.
In their concluding remarks, Hassel and colleagues reflected on their data regarding reduced circulating tumor DNA (ctDNA) at the 9-week mark before any treatment response was clear in their patients. As they observed a reduction in ctDNA correlating with overall survival—at rates that mimicked those witnessed in their phase 2 trial of tebentafusp—the authors believe these findings reinforce the need for additional investigations on the relationship between reduced ctDNA levels and tebentafusp. While their phase 3 results support the long-term benefits of tebentafusp in HLA-A*02:01-positive patients with metastatic uveal melanoma, they conclude by emphasizing avenues for future research efforts.
Reference
Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256-2266. doi:10.1056/NEJMoa2304753.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More